Sodium Alginate Gel Barrier Stabilizes Oral Peptide Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical preparations for oral treatment of inflammatory gastrointestinal diseases often fail to effectively address the underlying pathogenesis and regeneration processes in the gastrointestinal tract, leading to inadequate healing and increased risk of polymorbidity, especially in seniors, due to instability of short peptides in gastric enzymes and secondary acid formation from carbonate-based medications.
Innovation Solution
A pharmaceutical preparation comprising sodium alginate, dipeptide α-glutamyl-tryptophan (Glu-Trp) monosodium salt, and water, formulated to provide gastroprotective and hepatoprotective effects by stabilizing the gastric environment and enhancing mucosal regeneration, with a specific ratio of ingredients that prevent ulcer formation and improve immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If potassium hydrogen carbonate is added to regulate gastric acidity, then the acidity of gastric juice is reduced, but secondary acid formation occurs which is even stronger and can lead to heartburn and esophagitis
Solution Approach 1:
The patent removes potassium hydrogen carbonate from the formulation entirely, replacing it with sodium alginate and dipeptide α-glutamyl-tryptophan monosodium salt. This extraction of the problematic carbonate component eliminates the secondary acid formation mechanism while maintaining gastroprotective effects through alternative mechanisms.
Solution Approach 2:
Sodium alginate acts as an intermediary substance that forms a protective gel barrier in the stomach, mediating between the gastric environment and the mucosal tissue. This gel barrier provides buffering capacity without triggering the carbonate-bicarbonate cycle that leads to rebound hyperacidity.
2Ease of operation
If short peptides such as alpha-glutamyl-tryptophan dipeptide are administered orally, then enteral administration is convenient, but the peptides are unstable in gastric and small intestinal enzymes and break down into individual amino acids
Solution Approach 1:
The patent changes the chemical parameters of the peptide by converting it to its monosodium salt form (α-glutamyl-tryptophan monosodium salt). This parameter change increases the peptide's stability in the gastrointestinal environment while maintaining its biological activity and immunomodulatory effects.
Solution Approach 2:
The formulation creates a composite system combining sodium alginate with the dipeptide monosodium salt. The sodium alginate matrix provides a protective environment that enhances the stability of the peptide against enzymatic degradation while allowing controlled release and absorption.
3Device complexity
If conventional pharmaceutical preparations are used for oral treatment, then the treatment approach is simple, but they fail to effectively address the underlying pathogenesis and regeneration processes in the gastrointestinal tract
Solution Approach 1:
The patent creates a multi-functional formulation where sodium alginate provides mucosal protection and buffering, while the dipeptide α-glutamyl-tryptophan monosodium salt provides immunomodulatory and regenerative effects. This combination addresses multiple aspects of gastrointestinal pathology simultaneously, including inflammation, regeneration, and acid regulation.
Solution Approach 2:
The formulation merges two previously separate therapeutic approaches: the gastroprotective properties of sodium alginate and the immunomodulatory effects of the dipeptide. By combining these substances in a single oral preparation, the patent achieves synergistic effects that enhance overall healing effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The preparation demonstrates significant gastroprotective and hepatoprotective activities by reducing ulcer formation, improving body weight, and normalizing liver and pancreatic functions, with a safe and effective reduction in the severity of gastrointestinal and pancreatic damage, as evidenced by experimental and clinical studies.
Implementation Method 1
sodium alginate, a functional additive and water for the oral treatment of inflammatory gastrointestinal diseases
Implementation Method 2
regulate the acidity of the gastric juice
Implementation Method 3
thymogen (alpha-glutamyl tryptophan) has the ability to regulate the acidity of gastric juice
Implementation Method 4
the modulating influence of synthetic glycamyl-tryptophan dipeptide (thymogen) on the non-specific immune defense
Implementation Method 5
formulated to provide gastroprotective and hepatoprotective effects by stabilizing the gastric environment and enhancing mucosal regeneration
Implementation Method 6
with a specific ratio of ingredients that prevent ulcer formation
Data Source
AI summary
The invention relates to a peptide drug for oral administration. The pharmaceutical preparation in gel form contains sodium alginate, a functional additive, and water. The functional additive in the preparation is 0.07–0.13 mg of α-glutamyl-tryptophan dipeptide in the form of its monosodium salt per 10 ml dose. The sodium alginate content per dose of the preparation is 200–300 mg. This results in increased efficacy of the preparation in the treatment of inflammatory gastrointestinal diseases.